Bristol-Myers Squibb (BMY) faces cautious outlook despite post-earnings share gains

Bristol-Myers Squibb (BMY) shares have risen 13.6% over the six months ended May 14, 2026, outperforming the S&P 500 by 5.7 percentage points, but analysts remain cautious after the company’s first-quarter results. The stock recently traded at $55.77, or 9.2 times forward earnings. While that valuation is relatively modest, concerns center on weak long-term growth. Bristol-Myers’ revenue grew at a compound annual rate of just 1.4% over the past five years, while earnings per share declined 1.7% annually over the same period. Sell-side analysts expect revenue to fall 4% over the 12 months through May 14, 2027, suggesting demand pressure across the company’s product portfolio. The combination of recent share outperformance, shrinking projected sales and declining per-share profitability points to elevated downside risk despite the stock’s low earnings multiple.